GT Biopharma, Inc.
GT Biopharma is a clinical-stage biopharmaceutical company developing immuno-oncology products based on its TriKE and Dual Targeting TriKE platforms. The platforms are designed to harness patients’ natural killer cells to target cancer cells, with candidates aimed at hematologic malignancies and solid tumors, as well as potential autoimmune applications. Its pipeline includes GTB-3650, which targets CD33 in relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; GTB-5550, which targets B7-H3 in advanced solid tumors; and GTB-7550, in development for lupus and other autoimmune disorders. Development of its earlier candidate, GTB-3550, is suspended. GT Biopharma expects to make money through sales of its products if they are approved for marketing, and its license agreements provide for royalties on net sales of licensed products. It may advance candidates independently or through collaborations. The company relies on third-party manufacturers to produce and test its compounds. GT Biopharma is headquartered in San Francisco, California.
No enriched coverage for $GTBP in the last 7 days.
No SEC Form 4 filings for $GTBP in the last 30 days.
See all $GTBP insider activity →GT Biopharma reported preclinical results showing that combining its drug GTB-5550 with a KRAS inhibitor improved tumor control and immune response in pancreatic cancer models. The company is enrolling patients in a Phase 1a/1b trial for GTB-5550 as a standalone treatment and may explore a combination study. Success in human trials will be key for investors.
GT Biopharma, Inc. (GTBP) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. As previously disclosed, on November 20, 2025, GT Biopharma, Inc. (the “Company”) received a letter from the Nasdaq Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that its common stock, $0.001 par
GT Biopharma, Inc. (GTBP) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. Private Placement of Preferred Stock and Warrants As previously disclosed, on September 14, 2026, GT Biopharma, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Securities Purchase Agreement”) with the p
Recent GTBP coverage spans corporate actions, financial news and regulation.
GT Biopharma reported preclinical results showing that combining its drug GTB-5550 with a KRAS inhibitor improved tumor control and immune response in pancreatic cancer models. The company is enrolling patients in a Phase 1a/1b trial for GTB-5550 as a standalone treatment and may explore a combination study. Success in human trials will be key for investors.
Compliance restoration may lift sell pressure and enable continued Nasdaq listing.
The capital raise dilutes existing shareholders but provides cash for development, likely supporting short‑term price support.
The new large shareholder may influence voting outcomes and could signal confidence, potentially supporting the stock price.
Regulatory clearance may boost short-term upside but trial risk remains.
AlphAI scores every news story that mentions GTBP with an AI model for sentiment and relevance, and aggregates insider trades from GT Biopharma, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
GT Biopharma reported preclinical results showing that combining its drug GTB-5550 with a KRAS inhibitor improved tumor control and immune response in pancreatic cancer models. The company is enrolling patients in a Phase 1a/1b trial for GTB-5550 as a standalone treatment and may explore a combination study. Success in human trials will be key for investors.
GT Biopharma, Inc. (GTBP) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. As previously disclosed, on November 20, 2025, GT Biopharma, Inc. (the “Company”) received a letter from the Nasdaq Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that its common stock, $0.001 par
GT Biopharma, Inc. (GTBP) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. Private Placement of Preferred Stock and Warrants As previously disclosed, on September 14, 2026, GT Biopharma, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Securities Purchase Agreement”) with the p
RainForest Partners LLC disclosed a 9.99% stake in GT Biopharma (GTBP), owning 180,258 shares. The filing indicates sole voting and dispositive power, with a contractual limit of 9.99% ownership. GTBP has 1,804,380 outstanding shares as of September 8, 2026, according to the filing.
GT Biopharma (GTBP) received FDA clearance for GTB-5550, a B7-H3-targeted therapy, to begin Phase 1 trials in multiple myeloma. The trial, contingent on grant funding, will evaluate safety, tolerability, and anti-tumor activity. The company has $11M in cash, expected to last until Q3 2027. GTBP stock is down 22.96% to $8.96.
GT Biopharma, Inc. (GTBP) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. Private Placement of Preferred Stock and Warrants On September 14, 2026, GT Biopharma, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Securities Purchase Agreement”) with the purchasers identified ther
GT Biopharma (NASDAQ: GTBP) filed an 8-K on Aug. 14, 2026 after its Aug. 14 annual meeting. Stockholders elected four directors, ratified Weinberg & Company as auditor, and approved non-binding executive comp. They also approved a reverse stock split (1-for-10 to 1-for-30) and related authorized share reductions, plus 2022 plan share increases and an evergreen provision.
GT Biopharma, Inc. (GTBP) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07. Submission of Matters to a Vote of Security Holders. On August 14, 2026, GT Biopharma, Inc. (the “Company”) held its Annual Meeting of Stockholders (the “Annual Meeting”). The following is a brief description of the matters voted upon at the Annual Meeting, as well as
GT Biopharma (NASDAQ: GTBP) reported Q2 2026 results for the quarter ended June 30, 2026. It said Phase 1 TriKE candidates GTB-3650 (CD33+ leukemias) and GTB-5550 (B7-H3+ solid tumors) are enrolling, with updates expected in 2H 2026. Cash was about $5.1M, funding through Q4 2026. Q2 R&D was ~$1.1M, SG&A ~$3.4M, and net loss ~$4.5M.
GT Biopharma (NASDAQ: GTBP) says it has integrated AI tools into discovery and protein engineering for its tumor-targeting NK cell engagers and multi-domain proteins. The company expects efficiency gains that could move multiple new candidates into pre-IND development in 2027. Its TriKE-based programs include Phase 1 GTB-3650 (CD33) and GTB-5550 (B7-H3), with first patient dosed May 2026.
